Ocrelizumab marks an important milestone in research and treatment for progressive MS
Over 20 years ago, the first disease modifying therapy was approved in Canada for relapsing remitting MS, and since then we have seen…
Encouraging results presented at ECTRIMS Late Breaking News session
Perhaps the most anticipated session at ECTRIMS is “Late Breaking News”, which features a selection of exciting and newly released clinical trial results…
The need to preserve brain health among people with MS leads to development of recommendations for change
Today the research team met with Dr. Anthony Traboulsee here at ECTRIMS to talk about brain health. Dr. Traboulsee is an Associate Professor…
Update from ECTRIMS 2015: Day 2
It’s the second day of ECTRIMS 2015, and scientific seminars are in full swing – in fact, there are so many important topics…
Over 8,000 people expected in Barcelona for the world’s largest MS conference
This week, synergism, knowledge exchange and training in the MS field will take place as more than 8,000 people from around the world…
University of Waterloo students hack for MS wellness solutions
Last weekend the research team and I had the opportunity to head over to the Accelerator Centre in Waterloo and participate in Hack4Health,…
Mitochondria: How the power plants of our cells are linked to progressive MS
The destructive inflammation that strips nerve fibres in the central nervous system (CNS) of their myelin coating is the main culprit responsible for…
Progressive MS Alliance takes another giant step forward in the search for answers about progressive MS
Last week marked an important milestone in continuing efforts around the world to end progressive MS. By now I’m sure most of you…
Research Decoder: Outcome measures II – Imaging
In the last Research Decoder, I went over some of the most common clinical outcome measures used to evaluate the efficacy and safety…
Representing the public voice
During my years as vice-president of research at the MS Society, I’ve witnessed a change in how people with MS view research…